Abstracts tagged "Gene Expression and rheumatoid arthritis (RA)"

Abstract Number: 147 • 2013 ACR/ARHP Annual Meeting
Modular Analysis Of In Peripheral Blood Gene Expression In Rheumatoid Arthritis Captures Reproducible Gene Expression Changes In TNF Responders
Mark Curran¹, Michaela Oswald², Sarah Lamberth¹, Carrie Brodmerkel¹, Zhenya Cherkas¹ and Peter K. Gregersen³, ¹Janssen Research & Development, LLC., Spring House, PA, ²Laboratory of Genomics and Human Genetics, The Feinstein Institute for Medical Research, Manhasset, NY, ³Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: The use of whole blood gene expression to predict and follow the response to TNF inhibition therapy in RA has been challenging due to…
Abstract Number: 1882 • 2013 ACR/ARHP Annual Meeting
Characterizing The C-Type Lectin Domain Family 4, Member C Gene (CLEC4C) Expression In Peripheral Blood From Rheumatoid Arthritis Patients
Annie Yarwood¹, Joanna Cobb², Kate McAllister¹, Joanne Barnes¹, Ernst R. Dow³, Michelle A. Penny³, Robert W. Hoffman³ and Anne Barton^4,5, ¹Arthritis Research UK Epidemiology Unit, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Central Manchester Foundation Trust, Manchester, United Kingdom, ³Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, ⁴Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁵NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: A previous hypothesis-seeking study examining baseline phenotypic expression of mRNA in a Phase 2 clinical trial of tabalumab (also known as LA294 or LY2127399)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].